Shield Therapeutics.
68 announcements.
68 announcements.
| Time | Date | Ticker | Company | Announcement |
|---|---|---|---|---|
| 07:03 | 07-11-2025 | STX | Shield Therapeutics | ACCRUFeR receives Authorisation by Korean Ministry |
| 07:00 | 23-10-2025 | STX | Shield Therapeutics | Q3 2025 Trading Update |
| 15:01 | 14-10-2025 | STX | Shield Therapeutics | Grant of Share Options to Chief Executive Officer |
| 08:00 | 01-10-2025 | STX | Shield Therapeutics | Total Voting Rights |
| 07:02 | 01-10-2025 | STX | Shield Therapeutics | Positive efficacy and tolerance in pediatric trial |
| 07:00 | 15-09-2025 | STX | Shield Therapeutics | £1.5 million placing supporting growth of ACCRUFeR |
| 07:03 | 04-09-2025 | STX | Shield Therapeutics | ACCRUFeR® assigned Priority Review in US by FDA |
| 14:17 | 03-09-2025 | STX | Shield Therapeutics | Interim results for the six months ended 30 Jun 25 |
| 07:13 | 27-08-2025 | STX | Shield Therapeutics | Data published -European Journal of Heart Failure |
| 12:06 | 21-08-2025 | STX | Shield Therapeutics | Interim results for the six months ended 30 Jun 25 |
| 17:06 | 22-05-2025 | STX | Shield Therapeutics | Result of AGM |
| 07:06 | 24-04-2025 | STX | Shield Therapeutics | Audited results for the year ended 31 Dec 2024 |
| 07:01 | 22-04-2025 | STX | Shield Therapeutics | Licence Agreement in Japan for ACCRUFeR® |
| 11:23 | 17-04-2025 | STX | Shield Therapeutics | Q1 2025 Trading Update |
| 07:00 | 11-03-2025 | STX | Shield Therapeutics | ACCRUFeR® launched in Canada |
| 16:15 | 13-02-2025 | STX | Shield Therapeutics | PDMR Transaction Notification |
| 07:00 | 13-02-2025 | STX | Shield Therapeutics | Grant of Share Options |
| 07:00 | 05-02-2025 | STX | Shield Therapeutics | Unaudited full year trading update |
| 07:00 | 27-01-2025 | STX | Shield Therapeutics | Anders Lundstrom appointed CEO |
| 11:25 | 24-12-2024 | STX | Shield Therapeutics | Result of General Meeting & Total Voting Rights |
| 07:00 | 23-12-2024 | STX | Shield Therapeutics | Results of RetailBook Offer |
| 11:30 | 06-12-2024 | STX | Shield Therapeutics | Subscription by AOP Health to raise US$10 million |
| 11:31 | 06-12-2024 | STX | Shield Therapeutics | RetailBook Offer |
| 07:00 | 21-11-2024 | STX | Shield Therapeutics | Business Update |
| 07:00 | 29-10-2024 | STX | Shield Therapeutics | Q3 Trading Update |
| 07:00 | 25-09-2024 | STX | Shield Therapeutics | Results from Phase 3 paediatric study |
| 07:00 | 04-09-2024 | STX | Shield Therapeutics | Interim results |
| 07:00 | 27-08-2024 | STX | Shield Therapeutics | ACCRUFeR® Approved by Health Canada |
| 07:00 | 14-08-2024 | STX | Shield Therapeutics | Notice of interim results |
| 07:01 | 24-07-2024 | STX | Shield Therapeutics | Unaudited Q2 2024 Trading Update |
| 07:00 | 24-07-2024 | STX | Shield Therapeutics | Directorate Change |
| 07:00 | 03-07-2024 | STX | Shield Therapeutics | $5.7m Milestone Monetization Agreement with AOP |
| 16:25 | 20-06-2024 | STX | Shield Therapeutics | Results of 2024 Annual General Meeting |
| 07:00 | 28-05-2024 | STX | Shield Therapeutics | New Drug Application for Accrufer® in South Korea |
| 15:30 | 10-05-2024 | STX | Shield Therapeutics | Audited results for the year ended 31 Dec 2023 |
| 07:00 | 30-04-2024 | STX | Shield Therapeutics | Business Update for Q1 2024 |
| 07:00 | 21-02-2024 | STX | Shield Therapeutics | Unaudited Full Year Trading Update |
| 07:00 | 09-01-2024 | STX | Shield Therapeutics | Appointment of new Chief Financial Officer |
| 07:00 | 07-12-2023 | STX | Shield Therapeutics | Q3 2023 U.S. Commercial Highlights |
| 17:24 | 27-11-2023 | STX | Shield Therapeutics | PDMR Transaction Notification |
| 07:30 | 15-11-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team |
| 07:00 | 12-10-2023 | STX | Shield Therapeutics | Chief Financial Officer Transition |
| 15:00 | 03-10-2023 | STX | Shield Therapeutics | Result of REX Retail Offer |
| 07:00 | 03-10-2023 | STX | Shield Therapeutics | Block listing Interim Return |
| 07:00 | 03-10-2023 | STX | Shield Therapeutics | Completion of SWK Financing |
| 12:50 | 28-09-2023 | STX | Shield Therapeutics | Successful completion of US$6.1m Equity Fundraise |
| 07:02 | 28-09-2023 | STX | Shield Therapeutics | REX Retail Offer |
| 07:01 | 28-09-2023 | STX | Shield Therapeutics | $20m secured debt facility &proposed equity raise |
| 07:00 | 28-09-2023 | STX | Shield Therapeutics | Interim results update and business update |
| 07:00 | 06-09-2023 | STX | Shield Therapeutics | Notice of Results and Change in reporting currency |
| 09:45 | 25-07-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering |
| 07:00 | 20-07-2023 | STX | Shield Therapeutics | Business Update and U.S. Q2 2023 Highlights |
| 17:30 | 28-06-2023 | STX | Shield Therapeutics | Results of 2023 Annual General Meeting |
| 16:35 | 15-06-2023 | STX | Shield Therapeutics | Lapse of Offer |
| 07:00 | 15-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 07:00 | 14-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 07:00 | 13-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 07:00 | 12-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 07:00 | 09-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 07:00 | 08-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
| 10:10 | 06-06-2023 | STX | Shield Therapeutics | Grant of share options to the CEO |
| 11:00 | 01-06-2023 | STX | Shield Therapeutics | Holding(s) in Company |
| 10:55 | 01-06-2023 | STX | Shield Therapeutics | Holding(s) in Company |
| 07:00 | 31-05-2023 | STX | Shield Therapeutics | Total Voting Rights |
| 16:44 | 25-05-2023 | STX | Shield Therapeutics | Publication and posting of Offer Document |
| 07:00 | 19-05-2023 | STX | Shield Therapeutics | 2022 Annual Report and 2023 AGM Notice |
| 07:15 | 17-05-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions |
| 16:00 | 09-05-2023 | STX | Shield Therapeutics | Rule 2.9 Announcement and TVR Update |